Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
about
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced diseaseBrief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseThe balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infectionsGenomewide association analysis of respiratory syncytial virus infection in mice.Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccinePriming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengeRespiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse.Respiratory syncytial virus vaccinesPrevention of respiratory syncytial virus infections.Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infectionGinseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.Antiviral immunity and the role of dendritic cells.Ginseng protects against respiratory syncytial virus by modulating multiple immune cells and inhibiting viral replication.Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human InfantsA role for immune complexes in enhanced respiratory syncytial virus disease.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PEnhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSVIdentification of gene biomarkers for respiratory syncytial virus infection in a bronchial epithelial cell lineThe host response and molecular pathogenesis associated with respiratory syncytial virus infection.Human respiratory syncytial virus memphis 37 causes acute respiratory disease in perinatal lamb lung.Dendritic cells in viral bronchiolitis.Perinatal lamb model of respiratory syncytial virus (RSV) infection.Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity.Protection against respiratory syncytial virus infection by DNA immunization.Immunological responses to respiratory syncytial virus infection in infancy.Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virusAsthma and respiratory syncytial virus infection in infancy: is there a link?Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology.Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease.
P2860
Q21560951-FC3A5D8F-A27D-4B8E-9EE6-72FA0A313996Q26775152-E1D87CE2-652B-4978-A093-EA41CBE4C3CCQ33322528-84B1A74E-AEDD-4CDB-889F-BA80CA04E7E8Q33648868-C9819EE7-08DE-467E-94E4-1668134AF623Q33723524-EB7B0881-4413-4E91-8280-749103A75A5DQ33781642-85E56967-E4D7-469D-8CF7-F9D2B5E66707Q33783066-725541E8-627D-4236-BD49-A326641D21D5Q33807265-B5A7F187-1A90-4997-BB0A-D7490D9AF62CQ33975330-700BAB30-1F9B-42D9-A4E2-4DCE50AC668DQ34342190-403E7138-C04D-4AD7-A6ED-7EA2C67CF38DQ34355131-1733337D-DB87-418C-9897-A955006B25C4Q34440116-D032850B-C07A-4ED3-9455-B49EB9807172Q35027519-53243982-A668-4C5E-8D18-CAA2EDDC786FQ35131346-7B1D7BF4-1F12-4205-95D4-75A3D80EDE3DQ35634929-6F4B0F5A-6C8F-4A12-A0B3-D195ED8ABDF9Q35862041-6C086A5C-0FA3-4819-B7C8-E9655D5D4A7AQ36371267-842549BE-BD25-4BA3-8E92-B67477EEB492Q36464353-80C630F0-F7B5-4388-93A8-220722294A8FQ36922491-7F64ADAC-CE4C-4389-AE6D-7F9209AF9E33Q37002523-96B2D744-5EA2-46FB-BEB3-A09CE32CB313Q37223746-6F9C73F8-942E-4777-901A-7F2FAA518090Q37263779-4F856E2E-173D-4D76-A12E-6906AC3EBA6CQ37715621-C3BF4A5A-22AE-4B44-95BB-2E48CF781DD6Q37754636-3C7882FA-CF85-4EE3-B894-45EF9C624048Q40266020-165BB9AC-813A-438A-9B5A-01E013DAD818Q40708973-922F44EF-1CC8-4FBC-BA19-B8876C4B9616Q41907861-58F9D9E1-2B65-426C-B6D7-E02F67A2DBFEQ42084600-3128B634-6AD7-4F05-87EE-84E5E346BB3AQ42855455-1CDAEC36-9EFF-44B5-BFAB-D6E5D06A89AAQ44093134-381A43C3-8BEE-4999-9B36-E62309175AC1Q45735792-893A57BB-B347-4E5F-B26D-383C662D7A80Q45746586-8983F8D0-8178-40FF-B842-BCA36A68B48FQ45746926-3C61EEB0-0F86-4BAB-9C20-AA9A6BDB0E0F
P2860
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
@en
type
label
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
@en
prefLabel
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
@en
P2860
P356
P1476
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
@en
P2093
P2860
P356
10.1164/AJRCCM/152.4_PT_2.S63
P407
P433
P577
1995-10-01T00:00:00Z